SVF Vaccines
SVF Vaccines is a pre-revenue Swedish biotech developing DNA-based therapeutic and prophylactic vaccines for chronic hepatitis B/D and other serious infectious diseases, using a Karolinska Institutet–originated platform combining multiple viral genes to elicit antibody and T-cell responses.
- Company typePrivate
- Founded2015
- HeadquartersStockholm, Sweden
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What SVF Vaccines does
SVF Vaccines AB (formerly Svenska Vaccinfabriken Produktion AB) is a privately held Swedish biotechnology company headquartered in Stockholm, founded in 2015 and operating with a 1–10 employee team. The company develops vaccines and immunotherapies against serious infectious diseases using a proprietary DNA vaccine platform originated at Karolinska Institutet. The platform's design principle is the combination of multiple viral genes into chimeric constructs intended to elicit both neutralizing antibodies and T-cell responses, supporting both prophylactic and therapeutic vaccine applications.
The product pipeline is led by SVF-001, a therapeutic DNA vaccine for chronic hepatitis B (HBV) and hepatitis D (HDV) infections targeting 12 million HDV patients globally for whom no curative therapy exists; the program is preparing for Phase 1 clinical trials. SVF-002, a universal COVID-19 DNA vaccine targeting the spike, membrane and nucleoprotein of SARS-CoV-2, completed Phase 1 with positive safety and immunogenicity data in 2024. A Crimean-Congo Hemorrhagic Fever vaccine built on the same platform is in Phase 1 via Karolinska Institutet and the CCHF Vaccine consortium with European Commission funding. SVF holds US Patent 10,905,760 (granted February 2021) and a Notice of Allowance in Japan (April 2026) covering the HBV/HDV composition-of-matter. Karolinska Development (now KDventures AB) holds approximately 33% of the company.
SVF Vaccines is pre-revenue and monetizes through a licensing/royalty and partnership model, planning to out-license or exit via M&A to a pharmaceutical partner (the Gilead–Myr $1.7B HDV transaction is cited as a comparable exit). The company attempted to access public capital markets via a SEK 55M reverse takeover with Novakand Pharma on Nasdaq First North Premier, but Nasdaq rejected the listing in February 2026 and the transaction was terminated; a subsequent SEK 30M Phase 1 financing has not yet been replaced. Operational focus in 2026 is on advancing SVF-001 toward Phase 1 with new CEO Raheleh Nassaji and a cell-free DNA manufacturing partnership with Touchlight.
SVF Vaccines firmographics
Firmographics- Name
- SVF Vaccines
- Legal name
- SVF Vaccines AB
- Website
- https://svfvaccines.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- SVF Vaccines is a pre-revenue Swedish biotech developing DNA-based therapeutic and prophylactic vaccines for chronic hepatitis B/D and other serious infectious diseases, using a Karolinska Institutet–originated platform combining multiple viral genes to elicit antibody and T-cell responses.
- Ownership category
- akta.pro rank
SVF Vaccines industry classification
Industry- Product category
- Biotechnology Vaccines
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB)
- akta.pro secondary industries
- Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD), Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG), Pandemic Preparedness & Rapid-Response Vaccines (HLAIAEAF), Travel & Tropical Disease Vaccines (HLAIAEAE)
Keywords
Where SVF Vaccines is headquartered
LocationHeadquarters
- HQ city
- Stockholm
- HQ country
- Sweden
- HQ region
- Europe
Offices1 record
Markets served
SVF Vaccines business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Vaccine Development and Licensing: Pre-revenue biotech company. Planned to generate revenue through licensing deals, partnerships with pharmaceutical companies, and potential product commercialization after clinical development. Market for hepatitis D therapeutics estimated at 1 billion USD in 2032 with attractive exit landscape (e.g., Gilead acquisition of Myr for $1.7B in December 2020).
- Technology Platform Licensing: The company may generate revenue by licensing its vaccine technology platform developed at Karolinska Institutet to other pharmaceutical partners for additional vaccine applications.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
SVF Vaccines product offering
Product offeringCore offering
SVF Vaccines AB develops DNA-based vaccines and immunotherapies for serious infectious diseases, with its lead program SVF-001 being a therapeutic vaccine for chronic hepatitis B and D infections. The pipeline also includes SVF-002, a universal COVID-19 vaccine that completed a successful Phase 1 study, and a Crimean-Congo Hemorrhagic Fever vaccine in Phase 1 development. All candidates are built on a proprietary multi-specific immune response platform developed at Karolinska Institutet that combines different viral genes to generate both neutralizing antibodies and T-cell responses.
Product overview
SVF Vaccines develops vaccines and immunotherapies for serious infectious diseases using technology from Karolinska Institutet in Stockholm. The company operates a platform-based model with its lead product SVF-001, a therapeutic vaccine for chronic hepatitis B and D infections, currently preparing for Phase 1 clinical trials. The pipeline also includes SVF-002, a universal COVID-19 vaccine that completed Phase 1 trials, and a Crimean-Congo Hemorrhagic Fever vaccine in Phase 1 development. The underlying platform combines viral genes to generate both neutralizing antibodies and T cell responses.
Differentiator
Problem solved
Functional benefit
Products and services
- SVF-001 Therapeutic DNA vaccine immunotherapy for chronic hepatitis B (HBV) and D (HDV) virus infections, designed to induce antibodies and T cells targeting HDV to prevent entry into liver cells and eliminate infected cells, with the goal of reducing HDV levels and normalizing liver function. Currently advancing toward Phase 1 clinical trials for chronic hepatitis B/D patients with no curative treatment options.
- SVF-002 Universal DNA vaccine against SARS-CoV-2 (COVID-19) designed to elicit a broad neutralizing antibody response against the Spike (S) protein as well as T-cell responses against the Membrane (M) and Nucleoprotein (N) proteins, providing broader variant coverage than spike-only vaccines. Phase 1 clinical trial completed successfully with positive safety and immunogenicity data.
- Crimean-Congo Hemorrhagic Fever Vaccine DNA vaccine against Crimean-Congo Hemorrhagic Fever (CCHF) developed using SVF's DNA vaccine technology platform, currently in Phase 1 clinical trial funded by the European Commission and the CCHF Vaccine consortium, targeting a serious tick-borne viral hemorrhagic disease with high fatality.
Quantifiable outcome
- Sustained reductions in hepatitis D virus RNA for up to six weeks after treatment
- +2 more outcomes
Companies that use SVF Vaccines
Customer profileSegments2 records
Ideal customer profiles2 records
SVF Vaccines technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
SVF Vaccines partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and major.
- TouchlightcoreSVF Vaccines partnered with Touchlight, a biotechnology company specializing in cell-free DNA manufacturing, to accelerate the continued advancement of the Company's lead hepatitis B/D immunotherapy program, SVF-001, toward clinical development.
- Karolinska InstitutetcoreTechnology developed at Karolinska Institutet in Stockholm. Founders Matti Sällberg (CSO) and Lars Frelin are professors at Karolinska Institutet. The department of Laboratory Medicine at KI, led by Sällberg, provides ongoing research support.
- OpenCorona ConsortiumcoreSVF Vaccines collaborated with the OpenCorona consortium (funded by Horizon 2020) to develop and evaluate the universal Covid-19 vaccine SVF-002. The Phase 1 clinical study was conducted in collaboration with Karolinska University Hospital in Stockholm.
- Karolinska University HospitalmajorPhase 1 clinical study of SVF-002 universal Covid-19 vaccine was run by the OpenCorona consortium in collaboration with Karolinska University Hospital in Stockholm, Sweden.
Scale indicators5 records
Recent moves8 records
Expansion highlights5 records
SVF Vaccines competitors and assessment
Company assessmentBroad incumbents
- BioNTech: BioNTech develops mRNA-based infectious-disease and oncology vaccines, including COVID-19 and HBV therapeutic candidates. Comparable as a nucleic-acid vaccine platform player targeting the same disease space, though at vastly larger scale.
- Moderna: Moderna is the mRNA platform incumbent across infectious-disease vaccines including COVID-19 and is building toward HBV/HDV programs. Comparable on nucleic-acid vaccine technology, far larger scale and multi-indication pipeline.
- Gilead Sciences: Gilead acquired Myr (Hepcludex/bulevirtide) for $1.7B in December 2020 and is the dominant player in chronic HDV. Relevant as both a competitor and the most likely large-pharma acquirer of an HDV therapeutic like SVF-001.
Direct peers
- Arbutus Biopharma: Arbutus is a small-cap biotech focused on chronic HBV cure, developing RNAi and oral capsid inhibitors. Highly comparable to SVF on therapeutic-area focus (chronic HBV) and pipeline stage (pre-commercial, partner-seeking).
- Inovio Pharmaceuticals: Inovio is the leading clinical-stage DNA vaccine platform company, directly comparable to SVF on core technology (DNA plasmids with CELLECTRA electroporation delivery). Both target chronic infectious diseases (HPV, HBV) and pandemic preparedness with the same antigen-delivery modality.
- VBI Vaccines: VBI is a small-cap vaccine developer with programs in hepatitis B (Sci-B-Vac) and COVID-19. Comparable profile to SVF as a multi-platform, pre-commercial vaccine company targeting infectious diseases including HBV.
- Eiger BioPharmaceuticals: Eiger developed lonafarnib for HDV and hepatitis delta therapeutics, a direct competitor in the chronic HDV space. Comparable small-cap rare-disease biotech that pursued M&A exit (acquired by Senté Holdings).
- Vir Biotechnology: Vir develops immunotherapies and monoclonal antibodies for chronic HBV and other infectious diseases. Comparable as a clinical-stage infectious-disease biotech with partnered large-pharma structures and similar BD/licensing GTM.
- Replicor: Replicor is a small clinical-stage developer of HBsAg release agents (REP2139/REP2165) for chronic HBV/HDV. Direct therapeutic-area peer with identical hepatitis D focus and similar pre-revenue, partnership-dependent business model.
Emerging players
- Genexine: Genexine is a Korean biotech developing DNA and hybrid therapeutic vaccines for chronic HBV and oncology. Comparable early-stage platform peer targeting HBV immunotherapy with the same DNA-vaccine modality.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
SVF Vaccines social profiles
Digital presenceSVF Vaccines financial estimates
Financial estimateRevenue estimate
Valuation estimate
SVF Vaccines leadership team
Management profileNumber of profiles
Profiles9 records
SVF Vaccines funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SVF Vaccines M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SVF Vaccines
What does SVF Vaccines do?
SVF Vaccines AB develops DNA-based vaccines and immunotherapies for serious infectious diseases, with its lead program SVF-001 being a therapeutic vaccine for chronic hepatitis B and D infections. The pipeline also includes SVF-002, a universal COVID-19 vaccine that completed a successful Phase 1 study, and a Crimean-Congo Hemorrhagic Fever vaccine in Phase 1 development. All candidates are built on a proprietary multi-specific immune response platform developed at Karolinska Institutet that combines different viral genes to generate both neutralizing antibodies and T-cell responses.
Is SVF Vaccines a public or private company?
SVF Vaccines is a private company. It is classified as venture growth investor backed and is currently operating.
When was SVF Vaccines founded?
SVF Vaccines was founded in 2015. It employs 1 to 10 people.
Where is SVF Vaccines based?
SVF Vaccines is headquartered in Stockholm, Sweden, in the Europe region.
How does SVF Vaccines make money?
Two revenue lines are on record. Vaccine Development and Licensing is the primary driver. The others are technology Platform Licensing.
Who are SVF Vaccines's main competitors?
Broad incumbents on record are BioNTech, Moderna and Gilead Sciences. Direct peers are Arbutus Biopharma, Inovio Pharmaceuticals, VBI Vaccines, Eiger BioPharmaceuticals, Vir Biotechnology and Replicor. Genexine is listed as an emerging player.
Does SVF Vaccines have an API?
No public API is recorded for SVF Vaccines.
What industry is SVF Vaccines in?
SVF Vaccines's product category is Biotechnology Vaccines. Its primary akta.pro industry code is HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy), with a secondary code of HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA). Its SIC code is 2836.